Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 10
2011 5
2012 16
2013 8
2014 8
2015 19
2016 26
2017 26
2018 25
2019 30
2020 38
2021 35
2022 38
2023 34
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
NLRC5: new cancer buster?
Tang F, Xu Y, Zhao B. Tang F, et al. Mol Biol Rep. 2020 Mar;47(3):2265-2277. doi: 10.1007/s11033-020-05253-5. Epub 2020 Jan 10. Mol Biol Rep. 2020. PMID: 31925644 Review.
Nevertheless, increasing evidence has revealed that NLRC5 is up-regulated in some other tumors and promote tumor development and progression. The purpose of this review is to describe the role of NLRC5 in tumors and discuss whether NLRC5 can be a potential ta …
Nevertheless, increasing evidence has revealed that NLRC5 is up-regulated in some other tumors and promote tumor development and prog …
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Kim H, Kim H, Feng Y, Li Y, Tamiya H, Tocci S, Ronai ZA. Kim H, et al. Sci Transl Med. 2020 Jul 8;12(551):eaaz5683. doi: 10.1126/scitranslmed.aaz5683. Sci Transl Med. 2020. PMID: 32641491 Free PMC article.
PRMT5 methylation of IFI16 [interferon-gamma (IFN-gamma)-inducible protein 16] or its murine homolog IFI204, which are components of the cGAS/STING (stimulator of IFN genes) pathway, attenuated cytosolic DNA-induced IFN and chemokine expression in melanoma cells. PRMT5 also inhib …
PRMT5 methylation of IFI16 [interferon-gamma (IFN-gamma)-inducible protein 16] or its murine homolog IFI204, which are components of the cGA …
NLRC5: A Potential Target for Central Nervous System Disorders.
Zhang L, Jiao C, Liu L, Wang A, Tang L, Ren Y, Huang P, Xu J, Mao D, Liu L. Zhang L, et al. Front Immunol. 2021 Jun 18;12:704989. doi: 10.3389/fimmu.2021.704989. eCollection 2021. Front Immunol. 2021. PMID: 34220868 Free PMC article. Review.
Recent studies have found that NLRC5 is also associated with neuronal development and central nervous system (CNS) diseases, such as CNS infection, cerebral ischemia/reperfusion injury, glioma, multiple sclerosis, and epilepsy. This review summarizes the research progress …
Recent studies have found that NLRC5 is also associated with neuronal development and central nervous system (CNS) diseases, such as …
NLRC5: A paradigm for NLRs in immunological and inflammatory reaction.
Wu Y, Shi T, Li J. Wu Y, et al. Cancer Lett. 2019 Jun 1;451:92-99. doi: 10.1016/j.canlet.2019.03.005. Epub 2019 Mar 10. Cancer Lett. 2019. PMID: 30867141 Review.
NLRC5 has been demonstrated to be a potent negative regulator of NF-kappaB signaling pathway-mediated inflammatory response. Moreover, accumulating evidence has indicated that NLRC5 is closely related to pathological processes of various cancers. ...
NLRC5 has been demonstrated to be a potent negative regulator of NF-kappaB signaling pathway-mediated inflammatory response. Moreover …
Emerging Roles for NLRC5 in Immune Diseases.
Wang JQ, Liu YR, Xia Q, Chen RN, Liang J, Xia QR, Li J. Wang JQ, et al. Front Pharmacol. 2019 Nov 19;10:1352. doi: 10.3389/fphar.2019.01352. eCollection 2019. Front Pharmacol. 2019. PMID: 31824312 Free PMC article. Review.
Nevertheless, the paucity of absolute understanding of intrinsic characteristics and underlying mechanisms of NLRC5 still make it hard to develop targeting drugs. Therefore, current summary about NLRC5 information is indispensable. Herein, current knowledge of NL …
Nevertheless, the paucity of absolute understanding of intrinsic characteristics and underlying mechanisms of NLRC5 still make it har …
NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS. Yoshihama S, et al. Trends Cancer. 2017 Jan;3(1):28-38. doi: 10.1016/j.trecan.2016.12.003. Epub 2017 Jan 10. Trends Cancer. 2017. PMID: 28718425 Free PMC article. Review.
Recent genetic studies have revealed that NLRC5 is a major target for cancer immune evasion mechanisms. The reduced expression or activity of NLRC5 caused by promoter methylation, copy number loss, or somatic mutations is associated with defective MHC class I expres …
Recent genetic studies have revealed that NLRC5 is a major target for cancer immune evasion mechanisms. The reduced expression or act …
NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity.
Santharam MA, Shukla A, Levesque D, Kufer TA, Boisvert FM, Ramanathan S, Ilangumaran S. Santharam MA, et al. Int J Mol Sci. 2023 Apr 13;24(8):7206. doi: 10.3390/ijms24087206. Int J Mol Sci. 2023. PMID: 37108368 Free PMC article.
As the clinical application of NLRC5 is constrained by its large size, we examined whether a smaller NLRC5-CIITA fusion protein, dubbed NLRC5-superactivator (NLRC5-SA) as it retains the ability to induce MHC-I, could be used for tumor growth control. . …
As the clinical application of NLRC5 is constrained by its large size, we examined whether a smaller NLRC5-CIITA fusion protei …
NLRC5 Functions beyond MHC I Regulation-What Do We Know So Far?
Benkő S, Kovács EG, Hezel F, Kufer TA. Benkő S, et al. Front Immunol. 2017 Feb 17;8:150. doi: 10.3389/fimmu.2017.00150. eCollection 2017. Front Immunol. 2017. PMID: 28261210 Free PMC article. Review.
NLRC5 is a member of the NLR family that acts as a transcriptional activator of MHC class I genes. ...In human and murine cells, for example, NLRC5 was proposed to contribute to inflammatory and type I interferon responses. ...
NLRC5 is a member of the NLR family that acts as a transcriptional activator of MHC class I genes. ...In human and murine cells, for …
Macrophage-Specific NLRC5 Protects From Cardiac Remodeling Through Interaction With HSPA8.
Yu Q, Ju P, Kou W, Zhai M, Zeng Y, Maimaitiaili N, Shi Y, Xu X, Zhao Y, Jian W, Feinberg MW, Xu Y, Zhuang J, Peng W. Yu Q, et al. JACC Basic Transl Sci. 2023 Jan 18;8(5):479-496. doi: 10.1016/j.jacbts.2022.10.001. eCollection 2023 May. JACC Basic Transl Sci. 2023. PMID: 37325412 Free PMC article.
Myeloid-specific deletion of NLRC5 aggravated pressure overload-induced pathological cardiac remodeling and inflammation. Mechanistically, NLRC5 interacted with HSPA8 and suppressed NF-kappaB pathway in macrophages. ...
Myeloid-specific deletion of NLRC5 aggravated pressure overload-induced pathological cardiac remodeling and inflammation. Mechanistic …
NLRC5 Might Promote Endometrial Cancer Progression by Inducing PD-L1 Expression.
Zhu SD, Zhang J, Liu XJ, Zhang JH, Wei B, Wang WY, Fan YJ, Li D, Cao YX, Zhan L. Zhu SD, et al. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221112742. doi: 10.1177/15330338221112742. Technol Cancer Res Treat. 2022. PMID: 35880269 Free PMC article.
The mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. Conclusion: NLRC5 could inhibit the activation of PD-L1 in EC. Mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to …
The mutations of ANKRD20A2, C2orf42, ADGRB3, AVPR2, GOLGA6C, and IPPK may lead to the downregulation of NLRC5 in EC patients. Conclus …
304 results